What Is AHK-Cu? Research Evidence & Profile

What Is AHK-Cu?

AHK-Cu is a copper-containing tripeptide complex used in peptide-chemistry and coordination research contexts. This page identifies the material as Copper Tripeptide-3 (AHK-Cu). The AHK-Cu identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

0ClinicalTrials.gov query records

1PubMed query records

1Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for AHK-Cu is organized around copper-peptide coordination studies, short-peptide characterization, ligand and metal-complex analysis, and analytical peptide workflows. For AHK-Cu, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature1 important records shown

Selected Literature

Selected PubMed record

The effect of tripeptide-copper complex on human hair growth in vitro.

Archives of pharmacal research · 2007 Jul

PMID 17703734

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Copper Tripeptide-3 (AHK-Cu)
Available Specifications: 10mg, 20mg, 50mg
Pack Format: 10 Vials
Salt / Counter-Ion Form: Copper(II) coordination complex of AHK; the catalogue does not state a separate counter-ion stoichiometry.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for AHK-Cu

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

AHK-Cu Research Summary

Identity

Copper Tripeptide-3 (AHK-Cu); specifications: 10mg, 20mg, 50mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

0 registry records and 1 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

AHK-Cu is represented here by the catalogue identity Copper Tripeptide-3 (AHK-Cu). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg, 20mg, 50mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for AHK-Cu is organized around copper-peptide coordination studies, short-peptide characterization, ligand and metal-complex analysis, and analytical peptide workflows. For AHK-Cu, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 1 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

AHK-Cu FAQ

What is AHK-Cu?

What research records are indexed for AHK-Cu?

The synchronized query returned 0 ClinicalTrials.gov records and 1 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is AHK-Cu FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.